Abstract. In the present study, the role of Forkhead Box O1 (FOXO1) in glioblastoma (GBM) cell tumorigenesis was examined and the underlying mechanisms were investigated. Reverse transcription-quantitative polymerase chain reaction and western blot analyses were used to analyze the expression of FOXO1 in GBM cell lines (LN18 and T98G) and tissues. Compared with the control groups, FOXO1 was significantly downregulated in the GBM tissues and GBM cell lines (P<0.05). The effects of the expression of FOXO1 on GBM cell proliferation and cell cycle were examined using flow cytometry. The overexpression of FOXO1 markedly inhibited LN18 and T98G cell proliferation and arrested cell cycle at the G 0 /G 1 phase. In addition, FOXO1 facilitated cell senescence through regulation of the expression of sirtuin 1. Epithelial-mesenchymal transition (EMT) is a complex process, which affects cell growth, invasion and metastasis. The results of the present study revealed that FOXO1 inhibited EMT and metastasis in GBM. These finding revealed a novel mechanism of FOXO1 in the suppression of tumorigenesis and metastasis of GBM cells and suggested that FOXO1 may be a potential therapeutic target for treating GBM.
Introduction
Glioblastoma (GBM) has become the most aggressive and common type of central nervous system malignancy worldwide (1) . However, the causes of the carcinogenesis and progression of GBM remain to be elucidated. Several studies have indicated that the aberrant expression of the Forkhead Box (FOX) family protein has a key function in tumor growth, metastasis and response to cancer therapy (2-6).
The FOXO family includes FOXO1, FOXO3, FOXO4 and FOXO6. They all have a crucial function in gene transcription, which mediates cell processes, including DNA damage repair, apoptotic cell death, glucose metabolism, cell cycle control and carcinogenesis (7) . FOXO members consist of a conserved domain, which binds the DNA sequence TTGTTTAC at target gene (8, 9) . Several reports have demonstrated that FOXOs function in autophagy (10) (11) (12) . In oxidative stress, FOXO1 can promote autophagy, which may due to its tumor suppressor activity (13) .
Sirtuin 1 (SIRT1) is the mammalian orthologue of Sir2. It has been reported that SIRT1 has an important function in cell senescence (14, 15) . Nicotinamide adenine dinucleotide and nicotinamide can regulate the activity of SIRT1. The activation of SIRT1 protects cardiomyocytes from death and promotes the survival of neurons. In different tissues, SIRT1 has specific functions. For example, SIRT1 promotes gluconeogenesis and fatty acid oxidation under nutrient deprivation in the liver (16) . SIRT1 is also involved in pancreatic β-cell survival and insulin secretion through interacting with the FOXO family (17) and inhibiting of uncoupling protein 2 (18) , respectively.
Senescence is a state in which cells undergo specific alterations in gene expression and cellular morphology, accompanied by loss of the ability to proliferate. During cell senescence, β-galactosidase, which is associated with senescence, is activated, followed by cell cycle arrest at the G 0 /G 1 phase and a marked increase in the expression of cyclin-dependent kinase inhibitor (19, 20) .
In the present study, it was revealed that FOXO1 was significantly downregulated in the GBM tissues and GBM cell lines. FOXO1 inhibited cell proliferation via arresting the cell cycle at the G 0 /G 1 phase. In addition, FOXO1 facilitated cell senescence through regulation of sirtuin 1 expression. In addition, FOXO1 suppressed epithelial mesenchymal transition and metastasis. These findings suggested a novel mechanism of FOXO1 in the suppression of tumorigenesis and metastasis of GBM cells and suggested that FOXO1 may be a potential therapeutic target for treating GBM.
Fisher Scientific, Inc., Waltham, MA, USA) with 10% FBS (Sigma-Aldrich; Merck Millipore, Darmstadt, Germany) in 5% CO 2 at 37˚C.
Plasmid constructs and transfection. The human U87, T98G and LN18 GBM cells were grown in a 6-well plate to almost 70% confluence, follow by transfection with 3 µg of plasmids. The empty vector pcDNA3.1 plasmid and the FOXO1-containing plasmid 1 (pcDNA3.1-FOXO) were used (VigeneBio, Shandong, China). Transfection was performed using Lipofectamine ® 2000 reagent (Invitrogen; Thermo Fisher Scientific, Inc.), according to the manufacturer's protocol, for U87, T98G and LN18 transfection.
Cell cycle analysis. The cells were detatched using 0.25% trypsin and collected when the cells had reached almost 70-80% confluence, following which they were fixed with 75% ethanol overnight. ~3x10 4 cells were treated with 1 mg/ml RNase A (Sigma-Aldrich; Merck Millipore) at 37˚C for 40 min, resuspended in PBS and stained with propidium iodide for 30 min in the dark. Finally, the DNA contents were measured using a FACScan flow cytometry system. All experiments were performed three times.
Tissue samples. The 143 pairs' human GBM tissues and adjacent normal tissues were obtained from patients at The First Affiliated Hospital of China Medical University (Shenyang, China) between 2011 and 2015. All patients were diagnosed by pathological examination as having GBM. A total of 85 were male and 58 were female patients. The present study was approved by the Institutional Research Ethics Committee of The First Affiliated Hospital of China Medical University. All patients were informed and provided written informed consent. All tissue samples were collected and frozen in liquid nitrogen and stored at -80˚C until processing. The expression of FOXO1 in tissues was determined by reverse transcription-quantitative polymerase chain reaction (RT-qPCR). The mean value of FOXO1 content in tumor cells acted as the standard. Therefore, higher values than the standard value was denoted as high expression and lower values than the standard value was denoted as low expression.
MTT assay. An MTT assay was used to detect cell proliferation, as described previously (21) . In brief, the cells were seeded at 3x10 3 per well in a 96-well plate and incubated with 20 µl MTT (10 mg/ml in PBS; Sigma-Aldrich; Merck Millipore) at 37˚C for 3 h, follow by dissolving in DMSO. Finally, the density of cells was detected at 570 nm. Each assay was performed three times and all data presented as the mean ± standard deviation of the three experiments.
Western blot analysis. The cells were lysed in RIPA buffer containing 1% NP-40, 50 mM Tris-HCl (pH 7.4), 1 mM EDTA, 150 mM NaCl, 1 mM NaF, 0.25% Na-deoxycholate and 0.2 mM sodium orthovanadate, supplemented with protease inhibitor cocktail. The protein concentration was determined using BCA Protein Assay Reagent (Pierce; Thermo Fisher Scientific, Inc.). Subsequently, 50 µg of total protein was subjected to 10% SDS-PAGE and transferred onto PVDF membranes (EMD Millipore, Billerica, MD, USA). The membranes were then blocked in 5% skimmed milk at room temperature for 1 h. Subsequently, the membranes were incubated with primary antibodies at 4˚C overnight, washed with TBST at least three times and then incubated with HRP-conjugated secondary antibodies (1:6,000; cat. nos. ab6721 and ab6789; Abcam, Cambridge, UK) for 2 h at room temperature. This was followed by washing with TBST three times. The primary antibodies used were as follows: FOXO1 (1:3,000; cat. no. ab39670; Abcam); β-actin (1:5,000; cat. no. ab8227; Abcam); FLAG (1:5,000; cat. no. F7425; Sigma-Aldrich); EMT antibody sampler kit (1:2,000; cat. no. 9782; Cell Signaling Technology, Inc., Danvers, MA, USA); p16 (1:2,000; cat. no. ab118459; Abcam); p33 (1:3,000; cat. no. ab124893; Abcam); Lsh (1:2,000; cat. no. 7798; Cell Signaling Technology, Inc.); SIRT1 (1:5,000; cat. no. HPA006295; Sigma-Aldrich). β-actin served as a loading control. Finally, the proteins were visualized using ECL detection reagent (Beyotime Institute of Biotechnology, Dalian, China) according to the manufacturer's protocol. The blots were quantified using Image J software version 1.0 (National Institutes of Health, Bethesda, MD, USA).
RT-qPCR and data analyses. Total cellular RNAs were isolated using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.), following which a reverse transcription system (Promega A3500; Thermo Fisher Scientific, Inc.) was used for the synthesis of first strand cDNA. Quantitation of the indicated gene transcripts was performed using qPCR. The mRNA level of GAPDH was used as the internal control. A total of 1 µl cDNA sample, 1.5 µl primer (10 nM), 7.5 µl 2X MIX buffer and 5 µl RNase-free water were added. The qPCR conditions were as follows: 5 min at 95˚C, denaturation at 95˚C for 30 sec, annealing at 57˚C for 30 sec and extension at 72˚C for 40 sec, performed for 30 cycles. The primer pairs used were as follows: E-cadherin, forward 5'-AAT CTC AAG CTC ATG GAT AAC C-3' and reverse 5'-GCA GAA TCA GAA TTA GCA AAG C-3'; α-catenin, forward 5'-GCT GAA AGT TGT GGA AGA TGG-3' and reverse 5'-TTA TAG GCT GCG ACA TCA GG-3'; N-cadherin, forward 5'-TCA AAG CCT GGA ACA TAT GTG-39 and reverse 5'-TGT TTG AAA GGC CAT ATG TGG-3'; fibronectin, forward 5'-GAG TAA ACC TGA AGC TGA AGA G-3' and reverse 5'-TCA CCA ATC TTG TAG GAC TG-3'; GAPDH, forward 5'-ATG AGA AGT ATG ACA ACA GCC T-3' and reverse 5'-ATG GAC TGT GGT CAT GAG TC-3'; and SIRT1, forward 5'-GCA CTA ATT CCA AGT TCC ATA CC-3' and reverse 5'-GCA AAG TTT GGC ATA TTC ACC-3'. Relative mRNA expression was calculated by the 2 -ΔΔCq method (22) .
Luciferase activity assay. The cells were seeded at 5x10 4 in 6-well plates, followed by transfection with plasmids when the cells reached 70-80% confluence. The activities of luciferase following ~48 h transfection were quantified using an illuminometer (Centro LB 960; Berthold Technologies GmbH, Bad Wildbad, Germany). Each experiment was performed at least three times.
ChIP assay. A ChIP assay was performed using an EZ-ChIP kit (EMD Millipore) according to the manufacturer's protocol with minor modifications. In brief, the LN18 cells (~3x10 4 ) were used at a density of 80-90% confluence, and ChIP assays were performed using 5 µl anti-FOXO1 antibody (cat. no. ab39670; Abcam) at 4 at 44ntibod. The DNA was isolated from the immunoprecipitates and quantified using RT-qPCR analysis with the specific primer pairs: p16, forward 5'-CTCTTATACCAGGCAATGTA-3'; and reverse 5'-GTACGACTAGAAAGTGTCCC-3'; SIRT1, forward 5'-CAGATGGATTTCAGAGGGAT-3' and reverse 5'-GAAGGCTGAGGCAGGAGAAT-3'. A total of 2 µl sample, 1 µl primer (10 nM), 10 µl 2X MIX buffer and 7 µl RNase-free water were added. The qPCR conditions were as follows: 5 min at 95˚C, denaturation at 95˚C for 30 sec, annealing at 57˚C for 30 sec and extension at 72˚C for 40 sec, performed for 30 cycles. Input DNA and DNA immunoprecipitated by anti-IgG served as a positive and negative control, respectively.
Statistical analysis. All results were analyzed using SPSS v. 18.0 (SPSS, Inc., Chicago, IL, USA) and reported as the mean ± standard deviation. A paired samples t-test was used to compare between adjacent normal tissue and cancer tissues. P<0.05 was considered to indicate a statistically significant difference.
Results

FOXO1 is downregulated in human GBM cell lines and tissues.
In order to examine the function of FOXO1 in GBM in the present study, the expression levels of FOXO1 were determined in the LN18 and T98G GBM cell lines, and normal human astrocytes. The results demonstrated that the expression of FOXO1 was decreased at the protein and mRNA levels in these GBM cell lines, compared with the normal human astrocytes (Fig. 1A) . In addition, RT-qPCR analysis was performed to examine the mRNA levels of FOXO1 in seven paired human GBM tissues and adjacent normal tissues. Similar results were obtained, which showed the expression of FOXO1 was significantly downregulated in the GBM tissues, compared with that in the adjacent normal tissues (Fig. 1B) . Together, these results showed that FOXO1 was downregulated in GBM cell lines and primary tumors. Subsequently, the present study investigated the expression levels of FOXO1 in 143 patients with GBM. The RT-qPCR analysis revealed that the expression of FOXO1 was significantly downregulated in GBM. The expression of FOXO1 was negatively correlated with pathological grade (P<0.001), tumor size (P=0.003) and neck lymph node metastasis (P=0.01). However, differentiation, age and gender were not correlated with FOXO1 (Table I ). In addition, the present study investigated prognosis in the downregulation of FOXO1 in GBM. As expected, the survival curve indicated that the survival rates of patients with a high expression of FOXO1 were significantly higher, compared with those with low expression levels of FOXO1 (hazard ratio=1.49; P=0.024; Fig. 1C ).
FOXO1 inhibits GBM cell proliferation.
To further examine the role of FOXO1 in GBM, FLAG-FOXO1 was overexpressed in GBM cell lines, LN18 and T98G cells. RT-qPCR and western blot analyses were used to detect the transfection efficiency ( Fig. 2A and B) . Colony formation and MTT assays were also performed to investigate the function of FOXO1 in cell growth in GBM. The colony formation and MTT assays revealed that FOXO1 significantly decreased colony forming ability and cell growth in the LN18 and T98G cells ( Fig. 2C and D) . FOXO1 siRNA was also used to knock down FOXO1 in the LN18 and T98G cells, followed by analysis using colony formation and MTT assays. The depletion of FOXO1 increased the colony forming ability in cell proliferation of the LN18 and T98G cells (Fig. 2E) . To examine whether FOXO1 affected cell cycle progression, flow cytometry was used to detected cell cycle. The results revealed that the overexpression of FOXO1 arrested the cell cycle in the G 0 /G 1 phase, suppressing cells from entering the S phase (Fig. 2F) . By contrast, FOXO1 knockdown resulted in a higher number of cells entering the S phase, follow by promoted cell growth (Fig. 2G) . In brief, these findings demonstrated that FOXO1 arrested cells at the G 0 /G 1 phase and suppressed cell growth in GBM.
FOXO1 promotes senescence via the transcriptional inhibition of SIRT1. Following the induced overexpression of FOXO1, p16
INK4a was also expressed at a high level (Fig. 3A) . p16
INK4a has been reported to be expressed at high levels in cell senescence, in which it has a crucial function. Therefore, it was hypothesized that FOXO1 may be involved in cell senescence of GBM. There are several proteins associated with cell senescence, including histone deacetylase (HDAC)4, SIRT1, lymphoid specific helicase (Lsh) and p33 ING1b . To confirm this hypothesis, the present study investigated whether FOXO1 regulated these proteins. As shown in Fig. 3A , in LN18 cells overexpressing FOXO1, the expression of SIRT1 was suppressed, whereas HDAC4, Lsh and p33
ING1b
were not affected. The opposite results were obtained in the FOXO1-depleted cells, which showed SIRT1 was increased and p16
INK4a was decreased (Fig. 3B) . The mRNA levels of SIRT1 and p16
INK4a were also regulated by FOXO1, which suggested that FOXO1 regulated SIRT1 and p16
INK4a at the transcriptional level (Fig. 3C) . The present study then examined whether FOXO1 affected the transcription p16
INK4a or SIRT1. A ChIP assay was performed with FOXO1 antibody, which revealed that the SIRT1 promoter region interacted with FOXO1, whereas p16
IN4a did not interact with FOXO1. Although the mRNA and protein levels of p16
IN4a were affected by FOXO1, FOXO1 did not interact with its promoter region, therefore, FOXO1 may be indirectly regulated p16
IN4a by other proteins (Fig. 3D) . The luciferase reporter assay also confirmed that the recruitment of wide-type FOXO1 (wt-FOXO1) interacted with the SIRT1 promoter region and negatively regulated its transcription. However, FOXO1 (K245A) failed to regulate the transcription of SIRT1 (Fig. 3E) .
FOXO1 inhibits epithelial-mesenchymal transition (EMT) and metastasis in GBM.
To determine the role of FOXO1 in the EMT of GBM cells, the present study examined the expression of EMT markers in LN18 cells with FOXO1 depletion. The results showed that, at the mRNA and protein levels, the expression of epithelial markers, E-cadherin and α-catenin were decreased, and the expression of mesenchymal markers, N-cadherin, fibronectin and vimentin were increased (Fig. 4A) . The opposite results were observed in cells overexpressing FOXO1, where the expression of epithelial markers E-cadherin and α-catenin were significantly increased, and expression of mesenchymal markers N-cadherin, fibronectin and vimentin were decreased (Fig. 4B) . These results indicated that FOXO1 regulated EMT programming in the GBM cells. There are several reports indicating that EMT promotes cell invasion. In the present study, it was found that FOXO1 was negatively correlated with lymph node metastasis, therefore, FOXO1 may suppress GBM cell invasion. Transwell assays were performed to confirm this hypothesis; in the highly invasive human U87 GBM cancer cell line, the results indicated that, following knockdown of FOXO1, the number of invaded cells through Matrigel was almost three times as high as in the control, which revealed that the invasion ability of the U87 cells was enhanced when FOXO1 was knocked down (Fig. 4C) . By contrast, when FOXO1 was overexpressed, the number of invaded cells was decreased, compared with the number in the control group (Fig. 4C) . Therefore, FOXO1 affected the invasion ability of U87 cells. The present study also investigated the role of FOXO1 in anchorage-independent cell growth. As shown in Fig. 4D , the knockdown of FOXO1 in U87 cells significantly promoted colony formation. Therefore, FOXO1 has a key function in several cancer development processes, including EMT and cell invasion, and it also suppresses the anchorage-independent grow ability of cancer cell.
Discussion
In the present study, it was found that FOXO1 was significantly downregulated in GBM primary tumors and cell lines. The expression of FOXO1 was negatively correlated with clinical pathology, including neck lymph node metastasis (P=0.01) and tumor size (P=0.003). The K-M plot analysis survival curve also indicated that a high expression of FOXO1 in GBM was positively correlated with increased survival rates. Colony formation and MTT assays revealed that, following the ectopic expression of FOXO1, FOXO1 suppressed GBM cell growth. When FOXO1 siRNA was used to knock down FOXO1 in the GBM cells, the opposite results were obtained. The present study also found that the overexpression of FOXO1 arrested GBM cells at the G 0 /G 1 phase and inhibited cell proliferation, whereas FOXO1 knockdown released cells at the G 0 /G 1 phase for entry into the S phase.
The present study also found that the ectopic expression of FOXO1 resulted in p16
INK4a being expressed at a high level. The tumor suppressor p16
INK1a has been reported to be crucial in cell senescence (23) . Various types of stress result in decreased cell proliferation, following regulation by tumor suppressor genes, including p53, p16 INK4a and p21 (23, 24) . Several proteins have been found to be involved in cell senescence, including HDAC4, SIRT1, p33
ING1b and LSH (25) (26) (27) . The present study investigated whether FOXO1 affected the expression of these genes. The results showed that FOXO1 regulated the expression of SIRT1, but had no effect on the expression of HDAC, LSH or p33
ING1b
. The ChIP assay demonstrated that FOXO1 bound to the promoter region of SIRT1 in GBM cells, and decreased the mRNA and protein levels of SIRT1 in GBM cells. These results suggested that FOXO1 decreased the expression of SIRT1 at the transcriptional level and that FOXO1 promoted senescence via the transcriptional inhibition of SIRT1.
The data obtained in the present study demonstrated that FOXO1 inhibited EMT. EMT is a complex process in cancer cell development, which involves cancer cell growth, different, metastasis and other cell processes. The ectopic expression of FOXO1 markedly increased epithelial markers, including E-cadherin and α-catenin, whereas mesenchymal markers, N-cadherin, fibronectin and vimentin were all decreased. The opposite results were obtained when FOXO1 was silenced. Metastasis is a characteristic of malignant cancer and results in poor prognosis. EMT enhances the metastasis of cancer cells. As the present study found that FOXO1 was negatively correlated with neck lymph node metastasis, whether FOXO1 regulated cancer metastasis was determined using a Transwell assay. The results revealed FOXO1 suppressed GBM cell metastasis.
Taken together, the results of the present study revealed that FOXO1 was downregulated in GBM and, as a tumor suppressor, FOXO1 inhibited tumor growth and senescence via arresting cell cycle at the G0/G1 phase and inhibiting the transcription of SIRT1, respectively. FOXO1 also suppressed EMT and metastasis. These results provide evidence that FOXO1 may be a potential biomarker and therapeutic target for patients with GBM.
